NCT07030699View on ClinicalTrials.gov

A Study of Epcoritamab With Lenalidomide and Tafasitamab in People With Diffuse Large B Cell Lymphoma

PHASE2RecruitingINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

August 13, 2025

Primary Completion Date

August 31, 2028

Study Completion Date

August 31, 2028

Conditions
Lymphoma
Interventions
DRUG

Epcoritamab

Subcutaneous, once weekly in cycles 1-3; every 4 weeks cycles 4-12

DRUG

Lenalidomide

Oral, daily on days 1-21 of a 28-day cycle

DRUG

Tafasitamab

Intravenous, once weekly during cycles 1-3, then every 2 weeks during cycle 4-12

Trial Locations (7)

10065

RECRUITING

Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York

10604

RECRUITING

Memorial Sloan Kettering Westchester (All Protocol Activities), Harrison

11553

RECRUITING

Memorial Sloan Kettering Nassau (All Protocol Activities), Uniondale

11725

RECRUITING

Memorial Sloan Kettering Cancer Center Suffolk - Commack (All Protocol Activities), Commack

07920

RECRUITING

Memorial Sloan Kettering Basking Ridge (All Protocol Activities), Basking Ridge

07748

RECRUITING

Memorial Sloan Kettering Monmouth (All Protocol Activities), Middletown

07645

RECRUITING

Memorial Sloan Kettering Bergen (All Protocol Activities), Montvale

Sponsors

Collaborators (2)

Genmab
Incyte Corporation
All Listed Sponsors
collaborator

Genmab

INDUSTRY

collaborator

Incyte Corporation

INDUSTRY

lead

Memorial Sloan Kettering Cancer Center

OTHER